The American Journal of Medicine
Volume 121, Issue 4 , Pages 258-264 , April 2008

Complications of Viral Influenza

  • Michael B. Rothberg, MD, MPH

      Affiliations

    • Division of General Medicine, Baystate Medical Center, Springfield, Mass
    • Tufts University School of Medicine, Boston, Mass.
    • Corresponding Author InformationRequests for reprints should be addressed to Michael B. Rothberg, MD, MPH, Division of General Internal Medicine and Geriatrics, Baystate Medical Center, Springfield, MA 01199.
    • ,
  • Sarah D. Haessler, MD

      Affiliations

    • Division of Infectious Diseases, Baystate Medical Center, Springfield, Mass
    • Tufts University School of Medicine, Boston, Mass.
    • ,
  • Richard B. Brown, MD

      Affiliations

    • Division of Infectious Diseases, Baystate Medical Center, Springfield, Mass
    • Tufts University School of Medicine, Boston, Mass.

References 

  1. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179–186
  2. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292:1333–1340
  3. Simonsen L, Taylor R, Viboud C, et al. US flu mortality estimates are based on solid science. BMJ. 2006;332:177–178
  4. Simonsen L, Reichert TA, Viboud C, et al. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med. 2005;165:265–272
  5. Dushoff J, Plotkin JB, Viboud C, et al. Mortality due to influenza in the United States—an annualized regression approach using multiple-cause mortality data. Am J Epidemiol. 2006;163:181–187
  6. Rothberg M. Prioritizing influenza vaccination. JAMA. 2004;292:2582–2583
  7. Glezen WP, Decker M, Perrotta DM. Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston, 1978-1981. Am Rev Respir Dis. 1987;136:550–555
  8. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med. 2000;342:232–239
  9. Smith NM, Bresee JS, Shay DK, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55:1–42
  10. Hak E, Wei F, Nordin J, et al. Development and validation of a clinical prediction rule for hospitalization due to pneumonia or influenza or death during influenza epidemics among community-dwelling elderly persons. J Infect Dis. 2004;189:450–458
  11. Neuzil KM, Reed GW, Mitchel EF, et al. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol. 1998;148:1094–1102
  12. Schrag SJ, Fiore AE, Gonik B, et al. Vaccination and perinatal infection prevention practices among obstetrician-gynecologists. Obstet Gynecol. 2003;101:704–710
  13. Influenza vaccination in pregnancy: practices among obstetrician-gynecologists—United States, 2003-04 influenza season. MMWR Morb Mortal Wkly Rep. 2005;54:1050–1052
  14. Skiest DJ, Kaplan P, Machala T, et al. Clinical manifestations of influenza in HIV-infected individuals. Int J STD AIDS. 2001;12:646–650
  15. Klein MB, Lu Y, DelBalso L, et al. Influenzavirus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis. 2007;45:234–240
  16. Neuzil KM, Reed GW, Mitchel EF, Griffin MR. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA. 1999;281:901–907
  17. Fine AD, Bridges CB, De Guzman AM, et al. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis. 2001;32:1784–1791
  18. Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med. 2001;161:441–446
  19. Golden MP, Sajjad Z, Elgart L. Influenza and human immunodeficiency virus infection: absence of HIV progression after acute influenza infection. Clin Infect Dis. 2001;32:1366–1370
  20. Whimbey E, Champlin RE, Couch RB, et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis. 1996;22:778–782
  21. Vilchez RA, McCurry K, Dauber J, et al. Influenza virus infection in adult solid organ transplant recipients. Am J Transplant. 2002;2:287–291
  22. Louria DB, Blumenfeld HL, Ellis JT, et al. Studies on influenza in the pandemic of 1957-1958 (II. Pulmonary complications of influenza). J Clin Invest. 1959;38:213–265
  23. Murata Y, Walsh EE, Falsey AR. Pulmonary complications of interpandemic influenza A in hospitalized adults. J Infect Dis. 2007;195:1029–1037
  24. Oliveira EC, Marik PE, Colice G. Influenza pneumonia: a descriptive study. Chest. 2001;119:1717–1723
  25. Noble RL, Lillington GA, Kempson RL. Fatal diffuse influenzal pneumonia: premortem diagnosis by lung biopsy. Chest. 1973;63:644–646
  26. Peiris JS, de Jong MD, Guan Y. Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev. 2007;20:243–267
  27. The Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. N Engl J Med. 2005;353:1374–1385
  28. Treanor J. Influenza virus. In:  Mandell GL,  Bennett JE,  Dolin R editor. 6th ed.. Principles and Practice of Infectious Diseases. 162 vol.:Philadelphia: Churchill Livingstone; 2005;p. 2060–2085
  29. Schwarzmann SW, Adler JL, Sullivan RJ, Marine WM. Bacterial pneumonia during the Hong Kong influenza epidemic of 1968-1969. Arch Intern Med. 1971;127:1037–1041
  30. Chickering H, Park JH. Staphylococcus aureus pneumonia. JAMA. 1919;72:617–626
  31. Prechter GC, Gerhard AK. Postinfluenza toxic shock syndrome. Chest. 1989;95:1153–1154
  32. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis. 2006;12:894–899
  33. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza—Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep. 2007;56:325–329
  34. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev. 2006;19:571–582
  35. Lewis M, Kallenbach J, Ruff P, et al. Invasive pulmonary aspergillosis complicating influenza A pneumonia in a previously healthy patient. Chest. 1985;87:691–693
  36. Boots RJ, Paterson DL, Allworth AM, Faoagali JL. Successful treatment of post-influenza pseudomembranous necrotising bronchial aspergillosis with liposomal amphotericin, inhaled amphotericin B, gamma interferon and GM-CSF. Thorax. 1999;54:1047–1049
  37. Miyashita N, Matsushima T. Chlamydia pneumoniae infection during an influenza virus A epidemic: preliminary report. J Med Microbiol. 2000;49:391–392
  38. Gerber GJ, Farmer WC, Fulkerson LL. Beta-hemolytic streptococcal pneumonia following influenza. JAMA. 1978;240:242–243
  39. Garantziotis S, Howell DN, McAdams HP, et al. Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome. Chest. 2001;119:1277–1280
  40. Pinsker KL, Schneyer B, Becker N, Kamholz SL. Usual interstitial pneumonia following Texas A2 influenza infection. Chest. 1981;80:123–126
  41. Wilson CB, Smith RC. Goodpasture’s syndrome associated with influenza A2 virus infection. Ann Intern Med. 1972;76:91–94
  42. Rohde G, Wiethege A, Borg I, et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax. 2003;58:37–42
  43. Lin CY, Kuo YC, Liu WT, Lin CC. Immunomodulation of influenza virus infection in the precipitating asthma attack. Chest. 1988;93:1234–1238
  44. Foulkes W, Rees J, Sewry C. Influenza A and rhabdomyolysis. J Infect. 1990;21:303–304
  45. Studahl M. Influenza virus and CNS manifestations. J Clin Virol. 2003;28:225–232
  46. Hurwitz ES, Nelson DB, Davis C, et al. National surveillance for Reye syndrome: a five-year review. Pediatrics. 1982;70:895–900
  47. Barr CE, Mednick SA, Munk-Jorgensen P. Exposure to influenza epidemics during gestation and adult schizophrenia (A 40-year study). Arch Gen Psychiatry. 1990;47:869–874
  48. Ison MG, Campbell V, Rembold C, et al. Cardiac findings during uncomplicated acute influenza in ambulatory adults. Clin Infect Dis. 2005;40:415–422
  49. Jefferson TO, Rivetti D, Di Pietrantonj C, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2007;CD001269
  50. Rivetti D, Jefferson T, Thomas R, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2006;3:CD004876
  51. Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis. 2000;31:578–585
  52. Kang I, Hong MS, Nolasco H, et al. Age-associated change in the frequency of memory CD4+ T cells impairs long term CD4+ T cell responses to influenza vaccine. J Immunol. 2004;173:673–681
  53. Jefferson T. Influenza vaccination: policy versus evidence. BMJ. 2006;333:912–915
  54. Jackson LA, Jackson ML, Nelson JC, et al. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol. 2006;35:337–344
  55. Mangtani P, Cumberland P, Hodgson CR, et al. A cohort study of the effectiveness of influenza vaccine in older people, performed using the United Kingdom general practice research database. J Infect Dis. 2004;190:1–10
  56. Jackson LA, Nelson JC, Benson P, et al. Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. Int J Epidemiol. 2006;35:345–352
  57. Simonsen L, Viboud C, Blackwelder WC, et al. Researchers defend influenza vaccine study. Infectious Disease News. 2005;
  58. Wilde JA, McMillan JA, Serwint J, et al. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA. 1999;281:908–913
  59. Elder AG, O’Donnell B, McCruden EA, et al. Incidence and recall of influenza in a cohort of Glasgow healthcare workers during the 1993-4 epidemic: results of serum testing and questionnaire. BMJ. 1996;313:1241–1242
  60. Potter J, Stott DJ, Roberts MA, et al. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis. 1997;175:1–6
  61. Carman WF, Elder AG, Wallace LA, et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet. 2000;355:93–97
  62. Bright RA, Shay DK, Shu B, et al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA. 2006;295:891–894
  63. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364:759–765
  64. Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003-2006 influenza seasons. Wkly Epidemiol Rec. 2007;82:149–150
  65. Beigel JH, Farrar J, Han AM, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med. 2005;353:1374–1385
  66. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001;20:127–133
  67. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial (US Oral Neuraminidase Study Group). JAMA. 2000;283:1016–1024
  68. Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother. 1999;44(Suppl B):23–29
  69. Jefferson T, Deeks JJ, Demicheli V, et al. Amantadine and rimantadine for preventing and treating influenza A in adults. Cochrane Database Syst Rev. 2004;CD001169
  70. Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J. Antimicrob Chemother. 2003;51:123–129
  71. Lalezari J, Campion K, Keene O, Silagy C. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med. 2001;161:212–217
  72. Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163:1667–1672
  73. de Jong MD, Thanh TT, Khanh TH, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005;353:2667–2672
  74. Govorkova EA, Ilyushina NA, Boltz DA, et al. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother. 2007;51:1414–1424
  75. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–S72
  76. Coles FB, Balzano GJ, Morse DL. An outbreak of influenza A (H3N2) in a well immunized nursing home population. J Am Geriatr Soc. 1992;40:589–592
  77. Drinka PJ, Gravenstein S, Krause P, et al. Outbreaks of influenza A and B in a highly immunized nursing home population. J Fam Pract. 1997;45:509–514
  78. Arden NH, Patriarca PA, Fasano MB, et al. The roles of vaccination and amantadine prophylaxis in controlling an outbreak of influenza A (H3N2) in a nursing home. Arch Intern Med. 1988;148:865–868
  79. Dolin R, Reichman RC, Madore HP, et al. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med. 1982;307:580–584
  80. Peters PH, Gravenstein S, Norwood P, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc. 2001;49:1025–1031
  81. Schilling M, Povinelli L, Krause P, et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine. 1998;16:1771–1774
  82. Gravenstein S, Drinka P, Osterweil D, et al. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population. J Am Med Dir Assoc. 2005;6:359–366
  83. Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47:2554–2560
  84. Schlienger RG, Fedson DS, Jick SS, et al. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy. 2007;27:325–332
  85. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res. 2005;6:82
  86. Majumdar SR, McAlister FA, Eurich DT, et al. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ. 2006;333:999;Epub 2006 Oct 23
  87. Fedson DS. Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Infect Dis. 2006;43:199–205

PII: S0002-9343(08)00072-7

doi: 10.1016/j.amjmed.2007.10.040

The American Journal of Medicine
Volume 121, Issue 4 , Pages 258-264 , April 2008

Article Tools

* Image Usage & Resolution